Foundation Medicine and Collaborators to Present New Clinical Data on the Application of FoundationOne® at the 2015 Gastrointestinal Cancers Symposium

2015 Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass.--()--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new clinical data on the application of FoundationOne® will be presented during two oral presentations and one poster session at the 2015 Gastrointestinal Cancers Symposium taking place January 15-17, 2015, at the Moscone West Building in San Francisco.

“We look forward to sharing these data at the Gastrointestinal Cancers Symposium, and believe these findings provide further evidence for the clinical utility of FoundationOne, our flagship test for patients with solid tumors,” said Vincent Miller, M.D., chief medical officer, Foundation Medicine. “Collectively, these data from esophageal and biliary tract cancers show that our comprehensive genomic profiling capabilities continue to refine our understanding of disease biology and uncover treatment opportunities that might not have been otherwise considered for patients across all sub-types of cancer.”

The schedule for the podium presentations by Foundation Medicine is as follows:

Date & Time: Thursday, January 15, 2015, at 2 p.m. PT
Title: Comprehensive Genomic Profiling (CGP) of Advanced Stage Esophageal Squamous Cell Carcinomas (ESCC) and Esophageal Adenocarcinomas (EAC) Reveals Similarities and Differences
Abstract Number: 7
Session: Oral Abstract Session: Cancers of the Esophagus and Stomach
Presenting Author: Kai Wang, M.D., Ph.D., Senior Scientist, Foundation Medicine

Date & Time: Friday, January 16, 2015, at 7:55 a.m. PT
Title: Comprehensive Genomic Profiling of Biliary Tract Cancers Reveals Tumor-Specific Differences and a High Frequency of Clinically Relevant Genomic Alterations
Abstract Number: 231
Session: General Session 4: Ordering Molecular Profiling for Patients – Are We Ready?
Presenting Author: Jeffrey S. Ross, M.D., Medical Director, Foundation Medicine

The schedule for the poster presentation by Foundation Medicine and its collaborators is as follows:

Date & Time: Saturday, January 17, 2015, at noon PT
Title: Comprehensive Genomic Profiling of Cancer of the Appendix Reveals New Routes to Targeted Therapies
Session: General Poster Session C: Cancers Of The Colon, Rectum, And Anus
Presenting Author: Daniel A. Goldstein, Department of Hematology and Oncology, Winship Cancer Institute, Emory University

About FoundationOne®

FoundationOne, the company's first clinical product, is a fully informative genomic profile for solid tumors used by oncologists to identify the molecular alterations in a patient's tumor and match those alterations with relevant targeted therapies and clinical trials. Using next-generation sequencing in routine cancer specimens, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations, including base substitutions, insertions, deletions, copy number alterations and select rearrangements. FoundationOne fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. FoundationOne is a laboratory-developed test performed at Foundation Medicine's CLIA-certified lab. The test is accredited by CAP, is approved by the New York State Department of Health and has received a CE Mark. Please visit www.FoundationOne.com for more information.

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements for Foundation Medicine

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding presentations by Foundation Medicine at the 2015 Gastrointestinal Cancers Symposium and the presentation of evidence of the utility of Foundation Medicine's clinical assays to help inform the treatment of patients with gastrointestinal cancers. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that the evidence presented by Foundation Medicine may not demonstrate the utility of FoundationOne in the treatment of gastrointestinal cancers and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission, may be realized. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.

Contacts

Media Contact:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Foundation Medicine, Inc.
Khaled Habayeb, 617-418-2283
ir@foundationmedicine.com

Contacts

Media Contact:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Foundation Medicine, Inc.
Khaled Habayeb, 617-418-2283
ir@foundationmedicine.com